Miniaturized flow cytometry-based BCR-ABL immunoassay in detecting leptomeningeal disease

F. D&apos;Alessio; P. Mirabelli; E. Mariotti; M. Raia; R. di Noto; G. Fortunato; A. Camera; L. del Vecchio

doi:10.1016/j.leukres.2011.05.016

Miniaturized flow cytometry-based BCR-ABL immunoassay in detecting leptomeningeal disease

F. D'Alessio, P. Mirabelli, E. Mariotti, M. Raia, R. di Noto, G. Fortunato, A. Camera, L. del Vecchio

IRCCS SDN

Research output: Contribution to journal › Article › peer-review

Abstract

Despite central nervous system (CNS) prophylactic programs limit leptomeningeal involvement in acute lymphoblastic leukemia (ALL), it can still occur in a restricted percentage of cases. The exact risk rate remains still unknown, and several factors are associated with an increased probability to develop CNS involvement. Among them, Philadelphia (Ph)-positive genotype seems to play a relevant role. Recently, a flow cytometric assay to detect BCR-ABL protein has been developed, but little is known about its possible employment in leptomeningeal disease. Here, we show the miniaturized application of the original assay for BCR-ABL oncoprotein detection in cerebrospinal fluid (CSF) samples.

Original language	English
Pages (from-to)	1290-1293
Number of pages	4
Journal	Leukemia Research
Volume	35
Issue number	10
DOIs	https://doi.org/10.1016/j.leukres.2011.05.016
Publication status	Published - Oct 2011

Keywords

BCR-ABL oncoprotein
Cerebrospinal fluid
Flow cytometry
Immunobead assay
Philadelphia-positive leukemia

ASJC Scopus subject areas

Cancer Research
Hematology
Oncology

Access to Document

10.1016/j.leukres.2011.05.016

Cite this

@article{3dd21aa9ac814003b5c87f0784fdb8d8,

title = "Miniaturized flow cytometry-based BCR-ABL immunoassay in detecting leptomeningeal disease",

abstract = "Despite central nervous system (CNS) prophylactic programs limit leptomeningeal involvement in acute lymphoblastic leukemia (ALL), it can still occur in a restricted percentage of cases. The exact risk rate remains still unknown, and several factors are associated with an increased probability to develop CNS involvement. Among them, Philadelphia (Ph)-positive genotype seems to play a relevant role. Recently, a flow cytometric assay to detect BCR-ABL protein has been developed, but little is known about its possible employment in leptomeningeal disease. Here, we show the miniaturized application of the original assay for BCR-ABL oncoprotein detection in cerebrospinal fluid (CSF) samples.",

keywords = "BCR-ABL oncoprotein, Cerebrospinal fluid, Flow cytometry, Immunobead assay, Philadelphia-positive leukemia",

author = "F. D'Alessio and P. Mirabelli and E. Mariotti and M. Raia and {di Noto}, R. and G. Fortunato and A. Camera and {del Vecchio}, L.",

year = "2011",

month = oct,

doi = "10.1016/j.leukres.2011.05.016",

language = "English",

volume = "35",

pages = "1290--1293",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd",

number = "10",

}

TY - JOUR

T1 - Miniaturized flow cytometry-based BCR-ABL immunoassay in detecting leptomeningeal disease

AU - D'Alessio, F.

AU - Mirabelli, P.

AU - Mariotti, E.

AU - Raia, M.

AU - di Noto, R.

AU - Fortunato, G.

AU - Camera, A.

AU - del Vecchio, L.

PY - 2011/10

Y1 - 2011/10

N2 - Despite central nervous system (CNS) prophylactic programs limit leptomeningeal involvement in acute lymphoblastic leukemia (ALL), it can still occur in a restricted percentage of cases. The exact risk rate remains still unknown, and several factors are associated with an increased probability to develop CNS involvement. Among them, Philadelphia (Ph)-positive genotype seems to play a relevant role. Recently, a flow cytometric assay to detect BCR-ABL protein has been developed, but little is known about its possible employment in leptomeningeal disease. Here, we show the miniaturized application of the original assay for BCR-ABL oncoprotein detection in cerebrospinal fluid (CSF) samples.

AB - Despite central nervous system (CNS) prophylactic programs limit leptomeningeal involvement in acute lymphoblastic leukemia (ALL), it can still occur in a restricted percentage of cases. The exact risk rate remains still unknown, and several factors are associated with an increased probability to develop CNS involvement. Among them, Philadelphia (Ph)-positive genotype seems to play a relevant role. Recently, a flow cytometric assay to detect BCR-ABL protein has been developed, but little is known about its possible employment in leptomeningeal disease. Here, we show the miniaturized application of the original assay for BCR-ABL oncoprotein detection in cerebrospinal fluid (CSF) samples.

KW - BCR-ABL oncoprotein

KW - Cerebrospinal fluid

KW - Flow cytometry

KW - Immunobead assay

KW - Philadelphia-positive leukemia

UR - http://www.scopus.com/inward/record.url?scp=80052086278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052086278&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2011.05.016

DO - 10.1016/j.leukres.2011.05.016

M3 - Article

C2 - 21658767

AN - SCOPUS:80052086278

VL - 35

SP - 1290

EP - 1293

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 10

ER -

Miniaturized flow cytometry-based BCR-ABL immunoassay in detecting leptomeningeal disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this